Status:
COMPLETED
Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia
Lead Sponsor:
North Suffolk Mental Health Association
Collaborating Sponsors:
RespireRx
Conditions:
Schizophrenia
Eligibility:
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to evaluate the effects of a four-week trial of CX516 900mg tid compared to placebo upon verbal memory, attention and negative symptoms. The AMPA receptor positive modulat...
Eligibility Criteria
Inclusion
- Diagnosis of Schizophrenia, any subtype
- Ages 18-65 years
- Capable of providing informed consent
- Stable dose of clozapine, olanzapine or risperidone for at least 6 months
Exclusion
- Serious medical or neurological illness (unstable cardiac disease, seizure disorder, malignancy, liver or renal impairment, etc.)
- Current substance abuse
- Pregnancy, nursing, or unwilling to use appropriate birth control measures during participation if female and fertile
- Unable to complete neuropsychological tests
- History of serious blood dyscrasia requiring discontinuation of clozapine
- Serious suicidal or homicidal risk within the past six months
Key Trial Info
Start Date :
February 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2007
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT00235352
Start Date
February 1 2002
End Date
February 1 2007
Last Update
February 26 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Freedom Trail Clinic
Boston, Massachusetts, United States, 02114